[Evaluation of the in vitro activity of enoxacin on bacterial strains recently isolated in a hospital milieu].
The in vitro activity of enoxacin, a new quinolone derivative, was tested against 2180 bacterial strains, recently clinically isolated, by measuring the minimum inhibitory concentrations. Comparisons were made with other drugs (flumequine, oxolinic acid, pipemidic acid) widely utilized for the treatment of urinary tract infections. Enoxacin showed the highest activity against all the tested strains, with a geometrical mean of MICs (MG) of 0.39 micrograms/ml and a MIC 50 and MIC 90 of 0.25 and 4 micrograms/ml, respectively.
D000892:Anti-Infective Agents, Urinary / Q000494:pharmacology*; D003428:Cross Infection / Q000382:microbiology*; D004353:Drug Evaluation, Preclinical; D015365:Enoxacin; D024841:Fluoroquinolones; D006801:Humans; D009287:Naphthyridines / Q000494:pharmacology*; D010093:Oxolinic Acid / Q000494:pharmacology; D010876:Pipemidic Acid / Q000494:pharmacology; D011807:Quinolizines / Q000494:pharmacology; D014552:Urinary Tract Infections / Q000382:microbiology*
D000892:Anti-Infective Agents, Urinary; D024841:Fluoroquinolones; D009287:Naphthyridines; D011807:Quinolizines; D015365:Enoxacin; D010093:Oxolinic Acid; D010876:Pipemidic Acid; C012976:flumequine
Valutazione dell'attività in vitro dell'enoxacin su ceppi batterici di recente isolamento ospedaliero.